Free Trial

Aptose Biosciences Q1 2024 Earnings Report

Aptose Biosciences logo
$0.28 +0.11 (+63.92%)
(As of 12/20/2024 05:45 PM ET)

Aptose Biosciences EPS Results

Actual EPS
-$0.73
Consensus EPS
-$0.82
Beat/Miss
Beat by +$0.09
One Year Ago EPS
N/A

Aptose Biosciences Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Aptose Biosciences Announcement Details

Quarter
Q1 2024
Time
N/A

Conference Call Resources

The #1 Coin for November 2024 (Ad)

Grayscale Investments just announced a new fund offering access to a HOT new DeFi coin… And thanks to this newly established trust, I believe this coin could skyrocket up to 150x+ in the next 30 days alone! I've compiled everything you need to know about this once-in-a-lifetime DeFi project into a brand-new comprehensive guide…

You can get access to the report by clicking here now…

Aptose Biosciences Earnings Headlines

70%, 80%, 90% Win Rates? Grab Your Free Cheatsheets Today!
Would you like to know the historic win rate of every trade you take before you place it? Well, it’s all possible with these FIVE Candlestick Pattern Cheatsheets.
Aptose Biosciences granted extension to regain compliance with Nasdaq
Aptose Announces Positive Decision by Nasdaq Hearings Panel
See More Aptose Biosciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Aptose Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Aptose Biosciences and other key companies, straight to your email.

About Aptose Biosciences

Aptose Biosciences (NASDAQ:APTO), a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. The company has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Mississauga, Canada.

View Aptose Biosciences Profile

More Earnings Resources from MarketBeat

Upcoming Earnings